We are live on
!
Find out more
FLAM
First Light Asset Management Portfolio holdings
AUM
$1.12B
1-Year Est. Return
114.45%
This Fund
S&P 500
This Quarter
Est. Return
-0.93%
1 Year Est. Return
+114.45%
3 Year Est. Return
+266.49%
5 Year Est. Return
+454.92%
10 Year Est. Return
+8,470.94%
AUM
$1.52B
AUM Growth
-$149M
(-8.9%)
Cap. Flow
-$56.4M
Cap. Flow
% of AUM
-3.71%
Top 10 Holdings %
Top 10 Hldgs %
43.87%
Holding
86
New
7
Increased
23
Reduced
23
Closed
3
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BCYC
Bicycle Therapeutics
BCYC
|
+$25.6M |
| 2 |
PHLT
Performant Healthcare Inc
PHLT
|
+$19.6M |
| 3 |
Ultragenyx Pharmaceutical
RARE
|
+$19.2M |
| 4 |
State Street SPDR S&P Biotech ETF
XBI
|
+$15.7M |
| 5 |
MaxCyte
MXCT
|
+$15M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Arrowhead Research
ARWR
|
+$38.6M |
| 2 |
Glaukos
GKOS
|
+$34.7M |
| 3 |
Prothena Corp
PRTA
|
+$29.7M |
| 4 |
Halozyme
HALO
|
+$23.9M |
| 5 |
Genmab
GMAB
|
+$15.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 80.69% |
| 2 | Communication Services | 5.47% |
| 3 | Consumer Discretionary | 0.55% |
| 4 | Energy | 0.16% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
LITS
26
Lite Strategy Inc
LITS
$32.8M
| $23.8M | 1.57% |
431,874
+82,089
| +23% | +$4.52M |
|
|
AXNX
27
DELISTED
Axonics, Inc. Common Stock
AXNX
| $22.2M | 1.47% |
341,825
+8,952
| +3% | +$611K |
|
28
Alphatec Holdings
ATEC
$1.46B
| $21.6M | 1.43% |
1,774,668
+13,857
| +0.8% | +$193K |
|
|
ITMR
29
DELISTED
Itamar Medical Ltd. American Depository Shares
ITMR
| $20M | 1.32% |
662,969
+76,549
| +13% | +$1.69M |
|
|
PHLT
30
DELISTED
Performant Healthcare Inc
PHLT
| $17.6M | 1.16% |
+4,437,930
| New | +$19.6M |
|
|
YMAB
31
DELISTED
Y-mAbs Therapeutics
YMAB
| $16.5M | 1.09% |
577,663
-372,529
| -39% | -$11.7M |
|
32
Codexis
CDXS
$151M
| $16.3M | 1.07% |
699,716
-3,450
| -0.5% | -$81.6K |
|
33
KORU Medical Systems
KRMD
$189M
| $15.4M | 1.02% |
5,408,426
-15,921
| -0.3% | -$52.7K |
|
34
OrthoPediatrics
KIDS
$519M
| $15.2M | 1% |
232,492
+2,616
| +1% | +$170K |
|
35
SI-BONE Inc
SIBN
$788M
| $15.1M | 1% |
705,682
+1,452
| +0.2% | +$36.7K |
|
36
BioMarin Pharmaceuticals
BMRN
$11.6B
| $13.6M | 0.9% |
+176,559
| New | +$13.9M |
|
|
37
MaxCyte
MXCT
$112M
| $12.1M | 0.8% |
+994,670
| New | +$15M |
|
|
38
Genmab
GMAB
$17.7B
| $11.3M | 0.75% |
258,991
-348,055
| -57% | -$15.6M |
|
39
QuidelOrtho
QDEL
$1.14B
| $10.3M | 0.68% |
73,010
+586
| +0.8% | +$78.8K |
|
40
Neuronetics
STIM
$138M
| $9.57M | 0.63% |
1,458,818
-5,018
| -0.3% | -$48.1K |
|
|
SIEN
41
DELISTED
Sientra, Inc.
SIEN
| $9.04M | 0.6% |
157,776
+125,241
| +385% | +$8.55M |
|
42
Annexon
ANNX
$835M
| $9M | 0.59% |
483,773
+277,696
| +135% | +$5.63M |
|
|
APTO
43
DELISTED
Aptose Biosciences, Inc.
APTO
| $9M | 0.59% |
9,174
+29
| +0.3% | +$36.3K |
|
|
AKU
44
DELISTED
Akumin Inc
AKU
| $8.83M | 0.58% |
3,559,911
| – | – |
|
|
WW
45
DELISTED
WW International
WW
| $8.36M | 0.55% |
+458,273
| New | +$12M |
|
|
NVTA
46
DELISTED
Invitae Corporation
NVTA
| $7.29M | 0.48% |
256,367
+1,051
| +0.4% | +$30.8K |
|
47
Keros Therapeutics
KROS
$199M
| $6.85M | 0.45% |
+173,210
| New | +$6.16M |
|
48
Maravai LifeSciences
MRVI
$969M
| $5.83M | 0.38% |
118,703
-83,435
| -41% | -$4.07M |
|
49
The Joint Corp
JYNT
$118M
| $5.44M | 0.36% |
55,525
-61,238
| -52% | -$5.73M |
|
|
TCRR
50
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
| $5.28M | 0.35% |
620,887
-23,329
| -4% | -$330K |
|
Similar funds
AIM
MTCM
CNC
C
RIM
CT
SL
HH
First Light Asset Management's Q3 2021 Portfolio in Review
As of Q3 2021, First Light Asset Management held 86 positions worth $1.52B, down 8.9% from $1.67B the previous quarter. Its ten largest holdings account for 44% of the portfolio.
First Light Asset Management withdrew a net $56.4M in Q3 2021, closing 3 positions and reducing 23 holdings. Its most notable exit was Arrowhead Research, an estimated $38.6M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 81% of assets, down from 84% a quarter earlier, followed by Communication Services and Consumer Discretionary.
Against the trend, First Light Asset Management opened a new position in Bicycle Therapeutics worth $30.5M.
- First Light Asset Management's largest Q3 2021 buy was Bicycle Therapeutics: 732,731 shares worth $30.5M.
- First Light Asset Management added most to Ultragenyx Pharmaceutical in Q3 2021, an estimated $19.2M increase.
- First Light Asset Management's biggest Q3 2021 reduction was Prothena Corp, cutting an estimated $29.7M.
- First Light Asset Management fully exited Arrowhead Research in Q3 2021, selling an estimated $38.6M.
- First Light Asset Management's ten largest holdings make up 44% of its $1.52B portfolio in Q3 2021.
- First Light Asset Management opened 7 new positions and closed 3 in Q3 2021.
- First Light Asset Management's portfolio value fell 8.9% quarter-over-quarter to $1.52B.
Based on First Light Asset Management's 13F filing for Q3 2021, filed 12 Nov 2021.